HONG KONG – Amoy Diagnostics Co. Ltd. (Amoydx) received CFDA approval for its epidermal growth factor receptor (EGFR) mutation detection kit as a companion diagnostic for EGFR TKI (tyrosine kinase inhibitor)-based non-small-cell lung cancer (NSCLC) drugs.